Literature DB >> 29210937

RETINOBLASTOMA IN INDIA: Clinical Presentation and Outcome in 1,457 Patients (2,074 Eyes).

Swathi Kaliki1, Anamika Patel1, Sadiya Iram1, George Ramappa1, Ashik Mohamed2, Vijay A R Palkonda1.   

Abstract

PURPOSE: To study the clinical presentation, treatment, and outcome of patients with retinoblastoma (RB) in India.
METHODS: Retrospective study of 1,457 patients with RB (2,074 eyes).
RESULTS: The mean age at presentation of RB was 29 months (median, 24 months; range, <1-370 months). There were 812 (56%) men and 645 (44%) women with unilateral presentation of RB in 57% (n = 834) and bilateral in 43% (n = 623). Familial RB was present in 4% (n = 55). The most common presenting complaints included leukocoria (n = 1,100; 75%), proptosis (n = 91; 6%), strabismus (n = 77; 5%), and red eye (n = 68; 5%). Most (n = 1,889; 91%) tumors were intraocular in location, and 185 (n = 185; 9%) had extraocular tumor extension at presentation. The most common modalities of primary treatment-included systemic chemotherapy (n = 1,171; 60%) and enucleation (n = 674; 35%). At a mean follow-up period of 44 months (median, 30 months; range, 3-234 months), 92% (n = 1,206) were alive, and 108 (8%) patients died because of RB. Based on Kaplan-Meier analysis, the survival at 1, 3, 5, and 10 years was 94%, 91%, 90%, and 89%, respectively.
CONCLUSION: The most common presenting signs of RB in Asian Indian population are leukocoria and proptosis. With appropriate treatment, the survival rate is favorable at 92%.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 29210937     DOI: 10.1097/IAE.0000000000001962

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  14 in total

1.  Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand.

Authors:  Duangnate Rojanaporn; Taweevat Attaseth; Wimwipa Dieosuthichat; Kitikul Leelawongs; Samart Pakakasama; Usanarat Anurathapan; Ekachat Chanthanaphak; Sirintara Singhara Na Ayudhaya; Rangsima Aroonroch; Suradej Hongeng
Journal:  J Ophthalmol       Date:  2020-09-10       Impact factor: 1.909

2.  Survival outcomes of unilateral retinoblastoma based on pathological risk stratification-experience at a tertiary care centre in Pakistan.

Authors:  Najma Shaheen; Naila Inayat; Sehar Bashir; Umer Nisar Sheikh; Muhammad Abu Bakar; Palwasha Rehman
Journal:  Ecancermedicalscience       Date:  2022-03-01

3.  Second primary tumors in retinoblastoma survivors: a study of 7 Asian Indian patients.

Authors:  Swathi Kaliki; Vijay Anand Reddy Palkonda
Journal:  Int Ophthalmol       Date:  2020-07-31       Impact factor: 2.031

4.  Spectrum of germline RB1 mutations and clinical manifestations in retinoblastoma patients from Thailand.

Authors:  Duangnate Rojanaporn; Tatpong Boontawon; Takol Chareonsirisuthigul; Onrampa Thanapanpanich; Taweevat Attaseth; Duangporn Saengwimol; Usanarat Anurathapan; Tharikarn Sujirakul; Rossukon Kaewkhaw; Suradej Hongeng
Journal:  Mol Vis       Date:  2018-12-09       Impact factor: 2.367

5.  Clinicopathological Findings of Retinoblastoma: A 10-Year Experience from a Tertiary Hospital in Kampala, Uganda.

Authors:  James Joseph Yahaya; Belson Rugwizangoga; Alex Mremi; Asafu Munema
Journal:  J Ophthalmol       Date:  2019-06-16       Impact factor: 1.909

6.  Clinical characteristics, treatment and prognosis of children with unilateral retinoblastoma and intracranial segment of Retrobulbar optic nerve invasion.

Authors:  Yi-Zhuo Wang; Yi Zhang; Dong-Sheng Huang; Ji-Tong Shi; Jian-Min Ma; Bin Li; Xiao-Lin Xu; Yan Zhou; Hua-Li Gu
Journal:  BMC Ophthalmol       Date:  2021-01-14       Impact factor: 2.209

7.  Aurora Kinase B Expression, Its Regulation and Therapeutic Targeting in Human Retinoblastoma.

Authors:  Naheed Arfin Borah; Swatishree Sradhanjali; Manas Ranjan Barik; Atimukta Jha; Devjyoti Tripathy; Swathi Kaliki; Suryasnata Rath; Sunil K Raghav; Srinivas Patnaik; Ruchi Mittal; Mamatha M Reddy
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-03-01       Impact factor: 4.799

8.  Clinical Presentation of Retinoblastoma in Ethiopia: A Case of Jimma University Medical Center Pediatric Oncology Unit, Southwest Ethiopia.

Authors:  Diriba Fufa Hordofa; Kumale Tolesa Daba; Aemero Abateneh Mengesha
Journal:  Ethiop J Health Sci       Date:  2021-09

Review 9.  Retinoblastoma in Asia.

Authors:  Mukesh Jain; Duangnate Rojanaporn; Bhavna Chawla; Gangadhar Sundar; Lingam Gopal; Vikas Khetan
Journal:  Eye (Lond)       Date:  2018-11-01       Impact factor: 3.775

10.  Commentary: Retinoblastoma management-Where are we and where do we go from here?

Authors:  P Mahesh Shanmugam
Journal:  Indian J Ophthalmol       Date:  2020-11       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.